ERBB2 and pancreatic adenocarcinoma: The anti-HER2 antibody trastuzumab is a promising new candidate in the treatment of advanced pancreatic adenocarcinoma, because HER2 is overexpressed in a subset of ductal adenocarcinoms of the pancreas [16].